IL6 and congenital rubella syndrome: The most prevalent acute toxicity observed in CAR-T cell therapy is cytokine release syndrome (CRS), which is triggered by the release of inflammatory cytokines from CAR-T cells, leading to the production of critical cytokines like interleukin 6 (IL-6) by innate immune cells [4].